Guihong Chai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7050551/publications.pdf

Version: 2024-02-01

10	262	932766	1199166
12	262	10	12
papers	citations	h-index	g-index
12	12	12	462
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. International Journal of Nanomedicine, 2015, 10, 5671.	3.3	50
2	Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. International Journal of Pharmaceutics, 2020, 575, 118915.	2.6	43
3	Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa. Pharmaceutical Research, 2018, 35, 187.	1.7	37
4	Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model. International Journal of Pharmaceutics, 2019, 569, 118616.	2.6	23
5	Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats. Journal of Controlled Release, 2020, 327, 456-466.	4.8	23
6	Neutrophil Extracellular Traps Increase Airway Mucus Viscoelasticity and Slow Mucus Particle Transit. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 69-78.	1.4	23
7	Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. Drug Development and Industrial Pharmacy, 2010, 36, 1054-1063.	0.9	18
8	Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells. International Journal of Pharmaceutics, 2020, 586, 119570.	2.6	18
9	An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin. Journal of Pharmaceutical Analysis, 2021, 11, 732-738.	2.4	13
10	Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102262.	1.7	11
11	Transport features and structural optimization of solid lipid nanoparticles crossing the intestinal epithelium. RSC Advances, 2016, 6, 70433-70445.	1.7	2
12	Protective effect of polysaccharides on the stability of parenteral emulsions. Drug Development and Industrial Pharmacy, 2013, 39, 646-656.	0.9	1